tetano
Editor, Senior Moderator
Chem Biol Interact
. 2022 Jan 7;109796.
doi: 10.1016/j.cbi.2022.109796. Online ahead of print.
Cathepsin B is a potential therapeutic target for coronavirus disease 2019 patients with lung adenocarcinoma
Xiaoyan Ding[SUP] 1 [/SUP], Nan Ye[SUP] 1 [/SUP], Minyue Qiu[SUP] 1 [/SUP], Hongxia Guo[SUP] 1 [/SUP], Junjie Li[SUP] 1 [/SUP], Xiaoyang Zhou[SUP] 1 [/SUP], Maocheng Yang[SUP] 1 [/SUP], Jing Xi[SUP] 1 [/SUP], Yongjie Liang[SUP] 1 [/SUP], Yuanxin Gong[SUP] 1 [/SUP], Jintao Li[SUP] 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) was declared a serious global public health emergency. Hospitalization and mortality rates of lung cancer patients diagnosed with COVID-19 are higher than those of patients presenting with other cancers. However, the reasons for the outcomes being disproportionately severe in lung adenocarcinoma (LUAD) patients with COVID-19 remain elusive. The present study aimed to identify the possible causes for disproportionately severe COVID-19 outcomes in LUAD patients and determine a therapeutic target for COVID-19 patients with LUAD. We used publicly available data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases and various bioinformatics tools to identify and analyze the genes implicated in SARS-CoV-2 infection in LUAD patients. Upregulation of the SARS-CoV-2 infection-related molecules dipeptidyl peptidase 4, basigin, cathepsin B (CTSB), methylenetetrahydrofolate dehydrogenase, and peptidylprolyl isomerase B rather than angiotensin-converting enzyme 2 may explain the relatively high susceptibility of LUAD patients to SARS-CoV-2 infection. CTSB was highly expressed in the LUAD tissues after SARS-CoV-2 infection, and its expression was positively correlated with immune cell infiltration and proinflammatory cytokine expression. These findings suggest that CTSB plays a vital role in the hyperinflammatory response in COVID-19 patients with LUAD and is a promising target for the development of a novel drug therapy for COVID-19 patients.
Keywords: Cathepsin B; Hyperinflammatory response; Immune cell infiltration; Lung adenocarcinoma; SARS-CoV-2.
. 2022 Jan 7;109796.
doi: 10.1016/j.cbi.2022.109796. Online ahead of print.
Cathepsin B is a potential therapeutic target for coronavirus disease 2019 patients with lung adenocarcinoma
Xiaoyan Ding[SUP] 1 [/SUP], Nan Ye[SUP] 1 [/SUP], Minyue Qiu[SUP] 1 [/SUP], Hongxia Guo[SUP] 1 [/SUP], Junjie Li[SUP] 1 [/SUP], Xiaoyang Zhou[SUP] 1 [/SUP], Maocheng Yang[SUP] 1 [/SUP], Jing Xi[SUP] 1 [/SUP], Yongjie Liang[SUP] 1 [/SUP], Yuanxin Gong[SUP] 1 [/SUP], Jintao Li[SUP] 2 [/SUP]
Affiliations
- PMID: 35007526
- DOI: 10.1016/j.cbi.2022.109796
Abstract
Coronavirus disease 2019 (COVID-19) was declared a serious global public health emergency. Hospitalization and mortality rates of lung cancer patients diagnosed with COVID-19 are higher than those of patients presenting with other cancers. However, the reasons for the outcomes being disproportionately severe in lung adenocarcinoma (LUAD) patients with COVID-19 remain elusive. The present study aimed to identify the possible causes for disproportionately severe COVID-19 outcomes in LUAD patients and determine a therapeutic target for COVID-19 patients with LUAD. We used publicly available data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases and various bioinformatics tools to identify and analyze the genes implicated in SARS-CoV-2 infection in LUAD patients. Upregulation of the SARS-CoV-2 infection-related molecules dipeptidyl peptidase 4, basigin, cathepsin B (CTSB), methylenetetrahydrofolate dehydrogenase, and peptidylprolyl isomerase B rather than angiotensin-converting enzyme 2 may explain the relatively high susceptibility of LUAD patients to SARS-CoV-2 infection. CTSB was highly expressed in the LUAD tissues after SARS-CoV-2 infection, and its expression was positively correlated with immune cell infiltration and proinflammatory cytokine expression. These findings suggest that CTSB plays a vital role in the hyperinflammatory response in COVID-19 patients with LUAD and is a promising target for the development of a novel drug therapy for COVID-19 patients.
Keywords: Cathepsin B; Hyperinflammatory response; Immune cell infiltration; Lung adenocarcinoma; SARS-CoV-2.
